Emibetuzumab
- Generic Name
- Emibetuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1365287-97-3
- Unique Ingredient Identifier
- MO4K3GDN1I
- Background
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT02082210
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT01900652
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Iowa Hospital, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath